Liquidia (LQDA) and Pharmosa Biopharm have revised their licensing agreement concerning L606, an inhaled, sustained-release formulation of treprostinil under clinical trial for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This newly amended agreement extends Liquidia's licensed territory beyond North America to include significant markets in Europe, Japan, and other regions. Additionally, Liquidia has secured rights to use Pharmosa's next-generation smart-technology nebulizers with its liposomal drug formulations.
As part of these expanded exclusive rights, Liquidia will make an upfront payment of $3.5 million to Pharmosa, with the potential for up to $157.75 million in additional milestone payments tied to the development of PAH and PH-ILD indications and commercial sales outside North America.
